121 related articles for article (PubMed ID: 1599512)
1. Conversion of 5-iodo-2-pyrimidinone-2'-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design.
Chang CN; Doong SL; Cheng YC
Biochem Pharmacol; 1992 May; 43(10):2269-73. PubMed ID: 1599512
[TBL] [Abstract][Full Text] [Related]
2. Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine radiosensitization in U251 human glioblastoma xenografts.
Kinsella TJ; Vielhuber KA; Kunugi KA; Schupp J; Davis TW; Sands H
Clin Cancer Res; 2000 Apr; 6(4):1468-75. PubMed ID: 10778979
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of 5-iodo-2-pyrimidinone-2'-deoxyribose as a prodrug for 5-iodo-2'-deoxyuridine-mediated radiosensitization in mouse and human tissues.
Kinsella TJ; Kunugi KA; Vielhuber KA; Potter DM; Fitzsimmons ME; Collins JM
Clin Cancer Res; 1998 Jan; 4(1):99-109. PubMed ID: 9516958
[TBL] [Abstract][Full Text] [Related]
4. Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-deoxypyrimidinone-2'-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design.
Kinsella TJ; Schupp JE; Davis TW; Berry SE; Hwang HS; Warren K; Balis F; Barnett J; Sands H
Clin Cancer Res; 2000 Sep; 6(9):3670-9. PubMed ID: 10999760
[TBL] [Abstract][Full Text] [Related]
5. Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2'-deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts.
Seo Y; Yan T; Schupp JE; Radivoyevitch T; Kinsella TJ
Clin Cancer Res; 2005 Oct; 11(20):7499-507. PubMed ID: 16243824
[TBL] [Abstract][Full Text] [Related]
6. An in vivo comparison of oral 5-iodo-2'-deoxyuridine and 5-iodo-2-pyrimidinone-2'-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116.
Kinsella TJ; Kunugi KA; Vielhuber KA; McCulloch W; Liu SH; Cheng YC
Cancer Res; 1994 May; 54(10):2695-700. PubMed ID: 8168099
[TBL] [Abstract][Full Text] [Related]
7. IPdR: a novel oral radiosensitizer.
Saif MW; Berk G; Cheng YC; Kinsella TJ
Expert Opin Investig Drugs; 2007 Sep; 16(9):1415-24. PubMed ID: 17714027
[TBL] [Abstract][Full Text] [Related]
8. Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2'-deoxyribose.
Seo Y; Yan T; Schupp JE; Colussi V; Taylor KL; Kinsella TJ
Clin Cancer Res; 2004 Nov; 10(22):7520-8. PubMed ID: 15569982
[TBL] [Abstract][Full Text] [Related]
9. Phase I and Pharmacology Study of Ropidoxuridine (IPdR) as Prodrug for Iododeoxyuridine-Mediated Tumor Radiosensitization in Advanced GI Cancer Undergoing Radiation.
Kinsella T; Safran H; Wiersma S; DiPetrillo T; Schumacher A; Rosati K; Vatkevich J; Anderson LW; Hill KD; Kunos C; Collins JM
Clin Cancer Res; 2019 Oct; 25(20):6035-6043. PubMed ID: 31337643
[TBL] [Abstract][Full Text] [Related]
10. Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2'deoxyribose (IPdR) x 28 days in Fischer-344 rats: impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization.
Kinsella TJ; Kinsella MT; Hong S; Johnson JP; Burback B; Tosca PJ
Cancer Chemother Pharmacol; 2008 Feb; 61(2):323-34. PubMed ID: 17562042
[TBL] [Abstract][Full Text] [Related]
11. 5-iodo-2-pyrimidinone-2'-deoxyribose-mediated cytotoxicity and radiosensitization in U87 human glioblastoma xenografts.
Kinsella TJ; Kinsella MT; Seo Y; Berk G
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1254-61. PubMed ID: 17967315
[TBL] [Abstract][Full Text] [Related]
12. First-in-human phase 0 trial of oral 5-iodo-2-pyrimidinone-2'-deoxyribose in patients with advanced malignancies.
Kummar S; Anderson L; Hill K; Majerova E; Allen D; Horneffer Y; Ivy SP; Rubinstein L; Harris P; Doroshow JH; Collins JM
Clin Cancer Res; 2013 Apr; 19(7):1852-7. PubMed ID: 23403637
[TBL] [Abstract][Full Text] [Related]
13. Mechanism and mode of action of 5-iodo-2-pyrimidinone 2'-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells.
Lewandowski GA; Cheng YC
Mol Pharmacol; 1991 Jan; 39(1):27-33. PubMed ID: 1846219
[TBL] [Abstract][Full Text] [Related]
14. 5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase.
Porter DJ; Harrington JA; Almond MR; Lowen GT; Zimmerman TP; Spector T
Biochem Pharmacol; 1994 Mar; 47(7):1165-71. PubMed ID: 8161345
[TBL] [Abstract][Full Text] [Related]
15. Tissue distribution of the molybdenum hydroxylases, aldehyde oxidase and xanthine oxidase, in male and female guinea pigs.
Beedham C; Bruce SE; Rance DJ
Eur J Drug Metab Pharmacokinet; 1987; 12(4):303-6. PubMed ID: 3449390
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2'-deoxyribonucleosides.
Efange SM; Alessi EM; Shih HC; Cheng YC; Bardos TJ
J Med Chem; 1985 Jul; 28(7):904-10. PubMed ID: 2989522
[TBL] [Abstract][Full Text] [Related]
17. In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver.
Rashidi MR; Smith JA; Clarke SE; Beedham C
Drug Metab Dispos; 1997 Jul; 25(7):805-13. PubMed ID: 9224775
[TBL] [Abstract][Full Text] [Related]
18. Sulfoxide reductase activity of liver aldehyde oxidase.
Tatsumi K; Kitamura S; Yamada H
Biochim Biophys Acta; 1983 Sep; 747(1-2):86-92. PubMed ID: 6688361
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of aldehyde and xanthine oxidase in rat tissues using polyclonal antibodies.
Moriwaki Y; Yamamoto T; Yamaguchi K; Takahashi S; Higashino K
Histochem Cell Biol; 1996 Jan; 105(1):71-9. PubMed ID: 8824908
[TBL] [Abstract][Full Text] [Related]
20. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma.
Deutsch M; Rewers AB; Redgate S; Fisher ER; Boggs SS
Int J Radiat Oncol Biol Phys; 1990 Jul; 19(1):85-7. PubMed ID: 2380099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
